Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576

Neuropharmacology

Volumn 48, Issue 1, 2005, Pages 93-104

  Chauhan, Neelima B ^a,b,c   Siegel, George J ^c,d   Feinstein, Douglas L ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

A ; Alzheimer's disease; GSK 3 ; Nerve growth factor; Protein kinase C; Tau phosphorylation

Indexed keywords

AMYLOID; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; NERVE GROWTH FACTOR; PROPENTOFYLLINE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; IMMUNOREACTIVITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; SERINE; TAU PROTEINS; XANTHINES;

EID: 11144284662     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.09.014     Document Type: Article

References (96)

1. B.H. Anderton, J. Betts, W.P. Blackstock, J.P. Brion, S. Chapman, J. Connell, R. Dayanandan, J.M. Gallo, G. Gibb, D.P. Hanger, M. Hutton, E. Kardalinou, K. Leroy, S. Lovestone, T. Mack, C.H. Reynolds, and M. Van Slegtenhorst Sites of phosphorylation in tau and factors affecting their regulation Biochem. Soc. Symp. 67 2001 73 80
2. S. Capsoni, S. Giannotta, and A. Cattaneo Nerve growth factor and galantamine ameliorate early signs of Neurodegeneration in anti-nerve growth factor mice Proc. Natl. Acad. Sci. USA 99 19 2002 12432 12437
3. A. Caricasole, A. Copani, F. Caraci, E. Aronica, A.J. Rozemuller, A. Caruso, M. Storto, G. Gaviraghi, G.C. Terstappen, and F. Nicoletti Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain J. Neurosci. 24 26 2004 6021 6027
4. C.B. Chambers, E.M. Sigurdsson, M.J. Hejna, S.A. Lorens, J.M. Lee, and N.A. Muma Amyloid-beta injection in rat amygdala alters tau protein but not mRNA expression Exp. Neurol. 162 1 2000 158 170
5. N.B. Chauhan, and G.J. Siegel Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody J. Neurosci. Res. 69 1 2002 10 23
6. N.B. Chauhan, and G.J. Siegel Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg2576 brain Neurochem. Int. 43 3 2003 225 233
7. N.B. Chauhan, and G.J. Siegel Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576 J. Neurosci. Res. 74 1 2003 142 147
8. N.B. Chauhan, G.J. Siegel, and J.M. Lee Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain J. Chem. Neuroanat. 21 4 2001 277 288
9. J.H. Cho, and G.V. Johnson Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding J. Biol. Chem. 278 1 2003 187 193
10. J.M. Conner, M.A. Darracq, J. Roberts, and M.H. Tuszynski Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation Proc. Natl. Acad. Sci. USA 98 4 2001 1941 1946
11. P. Das, V. Howard, N. Loosbrock, D. Dickson, M.P. Murphy, and T.E. Golde Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice J. Neurosci. 23 24 2003 8532 8538
12. J. DeLeo, L. Toth, P. Schubert, K. Rudolphi, and G.W. Kreutzberg Ischemia-induced neuronal cell death, calcium accumulation, and glial response in the hippocampus of the Mongolian gerbil and protection by propentofylline (HWA 285) J. Cereb. Blood Flow Metab. 7 6 1987 745 751
13. B.W. Doble, and J.R. Woodgett GSK-3: tricks of the trade for a multi-tasking kinase J. Cell Sci. 116 Pt 7 2003 1175 1186
14. B. Dudas, U. Cornelli, J.M. Lee, M.J. Hejna, M. Walzer, S.A. Lorens, R.F. Mervis, J. Fareed, and I. Hanin Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain Neurobiol. Aging. 23 1 2002 97 104
15. W. Elyaman, C. Yardin, and J. Hugon Involvement of glycogen synthase kinase-3beta and tau phosphorylation in neuronal Golgi disassembly J. Neurochem. 81 4 2002 870 880
16. I. Ferrer, M. Barrachina, and B. Puig Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration Acta Neuropathol. (Berl.) 104 6 2002 583 591
17. K.B.J. Franklin, and G. Paxinos The Mouse Brain in Steretaxic Coordinates 1998 Academic Press New York
18. M. Frampton, R.J. Harvey, and V. Kirchner Propentofylline for dementia Cochrane Database Syst. Rev. 2 2003 CD002853
19. T. Fukuta, A. Nitta, A. Itoh, S. Furukawa, and T. Nabeshima Difference in toxicity of beta-amyloid peptide with aging in relation to nerve growth factor content in rat brain J. Neural Transm. 108 2 2001 221 230
20. K. Fuji, M. Hiramatsu, S. Hayashi, T. Kameyama, and T. Nabeshima Effects of propentofylline, a NGF synthesis stimulator, on alterations in muscarinic cholinergic receptors induced by basal forebrain lesion in rats Neurosci. Lett. 150 1 1993 99 102
21. A.C. Granholm Oestrogen and nerve growth factor - neuroprotection and repair in Alzheimer's disease Expert Opin. Invest. Drugs 9 4 2000 685 694
22. S.E. Hardt, and J. Sadoshima Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development Circ. Res. 90 10 2002 1055 1063
23. T. Ishii, H. Furuoka, Y. Muroi, and M. Nishimura Inactivation of integrin-linked kinase induces aberrant tau phosphorylation via sustained activation of glycogen synthase kinase 3beta in N1E-115 neuroblastoma cells J. Biol. Chem. 278 29 2003 26970 26975
24. K. Iqbal, C. Alonso Adel, E. El-Akkad, C.X. Gong, N. Haque, S. Khatoon, J.J. Pei, H. Tanimukai, I. Tsujio, J.Z. Wang, and I. Grundke-Iqba Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays J. Mol. Neurosci. 20 3 2003 425 429
25. R.S. Jope, and G.V. Johnson The glamour and gloom of glycogen synthase kinase-3 Trends Biochem. Sci. 29 2 2004 95 102
26. W. Kalback, M.D. Watson, T.A. Kokjohn, Y.M. Kuo, N. Weiss, D.C. Luehrs, J. Lopez, D. Brune, S.S. Sisodia, M. Staufenbiel, M. Emmerling, and A.E. Roher APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques Biochemistry 41 3 2002 922 928
27. T. Kawarabayashi, M. Shoji, L.H. Younkin, L. Wen-Lang, D.W. Dickson, T. Murakami, E. Matsubara, K. Abe, K.H. Ashe, and S.G. Younkin Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease J. Neurosci. 24 15 2004 3801 3809
28. K. Kobayashi, H. Nakano, M. Hayashi, M. Shimazaki, Y. Fukutani, K. Sasaki, K. Sugimori, and Y. Koshino Association of phosphorylation site of tau protein with neuronal apoptosis in Alzheimer's disease J. Neurol. Sci. 208 1-2 2003 17 24
29. Y. Koriyama, K. Chiba, and T. Mohri Propentofylline protects beta-amyloid protein-induced apoptosis in cultured rat hippocampal neurons Eur. J. Pharmacol. 458 3 2003 235 241
30. L.A. Kotilinek, B. Bacskai, M. Westerman, T. Kawarabayashi, L. Younkin, B.T. Hyman, S. Younkin, and K.H. Ashe Reversible memory loss in a mouse transgenic model of Alzheimer's disease J. Neurosci. 22 15 2002 6331 6335
31. H. Ksiezak-Reding, H.K. Pyo, B. Feinstein, and G.M. Pasinetti Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro Biochim. Biophys. Acta 1639 3 2003 159 168
32. S.P. Lad, K.E. Neet, and E.J. Mufson Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease Curr. Drug Target. CNS Neurol. Disord. 2 5 2003 315 334
33. L.F. Lau, and M.K. Ahlijanian Role of cdk5 in the pathogenesis of Alzheimer's disease Neurosignals 12 4-5 2003 209 214
34. G. Li, H. Yin, and J. Kuret Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules J. Biol. Chem. 279 16 2004 15938 15945
35. F. Liu, K. Iqbal, I. Grundke-Iqbal, and C.X. Gong Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta FEBS Lett. 530 1-3 2002 209 214
36. S.J. Liu, A.H. Zhang, H.L. Li, Q. Wang, H.M. Deng, W.J. Netzer, H. Xu, and J.Z. Wang Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory J. Neurochem. 87 6 2003 1333 1344
37. H.J. Luth, J. Apelt, A.O. Ihunwo, T. Arendt, and R. Schliebs Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice Brain Res. 977 1 2003 16 22
38. R.B. Maccioni, C. Otth, I.I. Concha, and J.P. Munoz The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology Eur J. Biochem. 268 6 2001 1518 1527
39. A. McRae, E.A. Ling, P. Schubert, and K. Rudolphi Properties of activated microglia and pharmacologic interference by propentofylline Alzheimer Dis. Assoc. Disord. 12 Suppl. 2 1998 S15 S20
40. N. Meskini, G. Nemoz, I. Okyayuz-Baklouti, M. Lagarde, and A.F. Prigent Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation Biochem. Pharmacol. 47 5 1994 781 788
41. G. Morfini, G. Szebenyi, R. Elluru, N. Ratner, and S.T. Brady Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility EMBO J. 21 3 2002 281 293
42. A. Mudher, S. Chapman, J. Richardson, A. Asuni, G. Gibb, C. Pollard, R. Killick, T. Iqbal, L. Raymond, I. Varndell, P. Sheppard, A. Makoff, E. Gower, P.E. Soden, P. Lewis, M. Murphy, T.E. Golde, H.T. Rupniak, B.H. Anderton, and S. Lovestone Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase J. Neurosci. 21 14 2001 4987 4995
43. A. Mudher, D. Shepherd, T.A. Newman, P. Mildren, J.P. Jukes, A. Squire, A. Mears, S. Berg, D. MacKay, A.A. Asuni, R. Bhat, and S. Lovestone GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila Mol. Psychiatry. 9 5 2004 522 530
44. G. Munch, J. Apelt, R. Kientsch-Engel, P. Stahl, H.J. Luth, and R. Schliebs Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. J. Neurochem. 86 2 2003 283 289
45. T. Nabeshima Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia [in Japanese] Yakugaku Zasshi 115 7 1995 499 512
46. T. Nabeshima, A. Nitta, and T. Hasegawa Impairment of learning and memory and the accessory symptom in aged rat as senile dementia model (3): Oral administration of propentofylline produces recovery of reduced NGF content in the brain of aged rats Yakubutsu Seishin Kodo 13 3 1993 89 95
47. T. Nabeshima, A. Nitta, K. Fuji, T. Kameyama, and T. Hasegawa Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats Gerontology 40 Suppl. 2 1994 46 56
48. I. Nishimura, Y. Yang, and B. Lu PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila Cell 116 5 2004 671 682
49. A. Nitta, Y. Ogihara, J. Onishi, T. Hasegawa, S. Furukawa, and T. Nabeshima Oral administration of propentofylline, a stimulator of nerve growth factor (NGF) synthesis, recovers cholinergic neuronal dysfunction induced by the infusion of anti-NGF antibody into the rat septum Behav. Brain Res. 83 1-2 1997 201 204
50. T. Ohkubo, Y. Mitsumoto, and T. Mohri Characterization of the uptake of adenosine by cultured rat hippocampal cells and inhibition of the uptake by xanthine derivatives Neurosci. Lett. 133 2 1991 275 278
51. C. Otth, I.I. Concha, T. Arendt, J. Stieler, R. Schliebs, C. Gonzalez-Billault, and R.B. Maccioni AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576 J. Alzheimers Dis. 4 5 2002 417 430
52. C. Otth, A. Mendoza-Naranjo, L. Mujica, A. Zambrano, I.I. Concha, and R.B. Maccioni Modulation of the JNK and p38 pathways by cdk5 protein kinase in a transgenic mouse model of Alzheimer's disease Neuroreport 14 18 2003 2403 2409
53. F.E. Parkinson, A.R. Paterson, J.D. Young, and C.E. Cass Inhibitory effects of propentofylline on [3H] adenosine influx. A study of three nucleoside transport systems Biochem. Pharmacol. 46 5 1993 891 896
54. A.L. Peel PKR activation in neurodegenerative disease J. Neuropathol Exp. Neurol. 63 2 2004 97 105
55. A.L. Peel, and D.E. Bredesen Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice Neurobiol. Dis. 14 1 2003 52 62
56. J.J. Pei, T. Tanaka, Y.C. Tung, E. Braak, K. Iqbal, and I. Grundke-Iqbal Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain J. Neuropathol. Exp. Neurol. 56 1 1997 70 78
57. J.J. Pei, H. Braak, C.X. Gong, I. Grundke-Iqbal, K. Iqbal, B. Winblad, and R.F. Cowburn Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration Acta Neuropathol. (Berl.) 104 4 2002 369 376
58. J.J. Pei, S. Khatoon, W.L. An, M. Nordlinder, T. Tanaka, H. Braak, I. Tsujio, M. Takeda, I. Alafuzoff, B. Winblad, R.F. Cowburn, I. Grundke-Iqbal, and K. Iqbal Role of protein kinase B in Alzheimer's neurofibrillary pathology Acta Neuropathol. (Berl.) 105 4 2003 381 392
59. G. Pigino, G. Morfini, A. Pelsman, M.P. Mattson, S.T. Brady, and J. Busciglio Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport J. Neurosci. 23 11 2003 4499 4508
60. R.A. Quintanilla, D.I. Orellana, C. Gonzalez-Billault, and R.B. Maccioni Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway Exp. Cell Res. 295 1 2004 245 257
61. M.P. Rathbone, P.J. Middlemiss, J.W. Gysbers, C. Andrew, M.A. Herman, J.K. Reed, R. Ciccarelli, P. Di Iorio, and F. Caciagli Trophic effects of purines in neurons and glial cells Prog. Neurobiol. 59 6 1999 663 690
62. C.H. Reynolds, J.C. Betts, W.P. Blackstock, A.R. Nebreda, and B.H. Anderton Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta J. Neurochem. 74 4 2000 1587 1595
63. S. Rossner, U. Ueberham, R. Schliebs, J.R. Perez-Polo, and V. Bigl p75 and TrkA receptor signaling independently regulate amyloid precursor protein mRNA expression, isoform composition, and protein secretion in PC12 cells J. Neurochem. 71 2 1998 757 766
64. S. Rossner, U. Ueberham, R. Schliebs, J.R. Perez-Polo, and V. Bigl The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling Prog. Neurobiol. 56 5 1998 541 569
65. S. Sato, Y. Tatebayashi, T. Akagi, D.H. Chui, M. Murayama, T. Miyasaka, E. Planel, K. Tanemura, X. Sun, T. Hashikawa, K. Yoshioka, K. Ishiguro, and A. Takashima Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells J. Biol. Chem. 277 44 2002 42060 42065
66. M.J. Savage, Y.G. Lin, J.R. Ciallella, D.G. Flood, and R.W. Scott Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition J. Neurosci. 22 9 2002 3376 3385
67. P. Schubert, and K. Rudolphi Interfering with the pathologic activation of microglial cells and astrocytes in dementia Alzheimer Dis. Assoc. Disord. 12 Suppl. 2 1998 S21 S28
68. P. Schubert, K.A. Rudolphi, B.B. Fredholm, and Y. Nakamura Modulation of nerve and glial function by adenosine - role in the development of ischemic damage Int. J. Biochem. 26 10-11 1994 1227 1236
69. P. Schubert, T. Ogata, K. Rudolphi, C. Marchini, A. McRae, and S. Ferroni Support of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline Ann. N. Y. Acad. Sci. 826 1997 337 347
70. P. Schubert, T. Ogata, C. Marchini, and S. Ferroni Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target? Mech. Ageing Dev. 123 1 2001 47 57
71. A. Sengupta, Q. Wu, I. Grundke-Iqbal, K. Iqbal, and T.J. Singh Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5 Mol Cell Biochem. 167 1-2 1997 99 105
72. I. Shinoda, Y. Furukawa, and S. Furukawa Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells Biochem. Pharmacol. 39 11 1990 1813 1816
73. Q.S. Si, Y. Nakamura, P. Schubert, K. Rudolphi, and K. Kataoka Adenosine and propentofylline inhibit the proliferation of cultured microglial cells Exp. Neurol. 137 2 1996 345 349
74. Q. Si, Y. Nakamura, T. Ogata, K. Kataoka, and P. Schubert Differential regulation of microglial activation by propentofylline via cAMP signaling Brain Res. 812 1-2 1998 97 104
75. Siegel, G.J., Chauhan, N.B., Karczmar, A.G., 2004. Linking amyloid and tau biology in Alzheimer's disease and its cholinergic aspects, In: Karczmar, A.G. (Ed.), The Rise of Research on the Cholinergic Central Nervous System. Kluwer/Academic/Plenum, New York, in press.
76. E.M. Sigurdsson, S.A. Lorens, M.J. Hejna, X.W. Dong, and J.M. Lee Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats Neurobiol. Aging 17 6 1996 893 901
77. B.R. Sperber, S. Leight, M. Goedert, and V.M. Lee Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells Neurosci. Lett. 197 2 1995 149 153
78. M. Takanashi, H. Mori, K. Arima, Y. Mizuno, and N. Hattori Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration Brain Res. Mol. Brain Res. 104 2 2002 210 219
79. R.D. Terry The cytoskeleton in Alzheimer disease J. Neural Transm. Suppl. 53 1998 141 145
80. Y. Tomidokoro, Y. Harigaya, E. Matsubara, M. Ikeda, T. Kawarabayashi, T. Shirao, K. Ishiguro, K. Okamoto, S.G. Younkin, and M. Shoji Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau J. Pathol. 194 4 2001 500 506
81. Y. Tomidokoro, K. Ishiguro, Y. Harigaya, E. Matsubara, M. Ikeda, J.M. Park, K. Yasutake, T. Kawarabayashi, K. Okamoto, and M. Shoji Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice Neurosci. Lett. 299 3 2001 169 172
82. L.H. Tsai, M.S. Lee, and J. Cruz Cdk5, a therapeutic target for Alzheimer's disease? Biochim. Biophys. Acta 1697 1-2 2004 137 142
83. M.A. Utton, A. Vandecandelaere, U. Wagner, C.H. Reynolds, G.M. Gibb, C.C. Miller, P.M. Bayley, and B.H. Anderton Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-assembly Biochem, J. 323 Pt 3 1997 741 747
84. U. Wagner, M. Utton, J.M. Gallo, and C.C. Miller Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation J. Cell Sci. 109 Pt 6 1996 1537 1543
85. L.C. Walker, M.J. Callahan, F. Bian, R.A. Durham, A.E. Roher, and W.J. Lipinski Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice Peptides 23 7 2002 1241 1247
86. L.C. Walker, F. Bian, M.J. Callahan, W.J. Lipinski, R.A. Durham, and H. LeVine Modeling Alzheimer's disease and other proteopathies in vivo: is seeding the key? Amino Acids 23 1-3 2002 87 93
87. L.H. Wang, C.G. Besirli, and E.M. Johnson Jr. Mixed-lineage kinases: a target for the prevention of neurodegeneration Annu. Rev. Pharmacol. Toxicol. 44 2004 451 474
88. F. Wirtz-Brugger, and A. Giovanni Guanosine 3′,5′-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline Neuroscience 99 4 2000 737 750
89. J.R. Woodgett Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders Curr. Drug Targets Immune Endocr. Metab. Disord. 3 4 2003 281 290
90. K. Yamada, A. Nitta, T. Hasegawa, K. Fuji, M. Hiramatsu, T. Kameyama, Y. Furukawa, K. Hayashi, and T. Nabeshima Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease Behav. Brain Res. 83 1-2 1997 117 122
91. K. Yamada, T. Tanaka, K. Senzaki, T. Kameyama, and T. Nabeshima Propentofylline improves learning and memory deficits in rats induced by beta-amyloid protein-(1-40) Eur J. Pharmacol. 349 1 1998 15 22
92. H. Yamaguchi, K. Ishiguro, T. Uchida, A. Takashima, C.A. Lemere, and K. Imahori Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II Acta Neuropathol. (Berl.) 92 3 1996 232 241
93. H. Yoshida, C.J. Hastie, H. McLauchlan, P. Cohen, and M. Goedert Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK) J. Neurochem. 90 2 2004 352 358
94. A. Yoshioka, Y. Shimizu, G. Hirose, H. Kitasato, and D. Pleasure Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity J. Neurochem. 70 6 1998 2416 2423
95. A. Yoshioka, Y. Yamaya, S. Saiki, M. Kanemoto, G. Hirose, and D. Pleasure Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell line J. Neurochem. 74 2 2000 633 640
96. X. Zhu, A.K. Raina, H.G. Lee, G. Casadesus, M.A. Smith, and G. Perry Oxidative stress signaling in Alzheimer's disease Brain Res. 1000 1-2 2004 32 39